Join us for an engaging and insightful session with Prof. Michelle Mielke of Wake Forest University and Prof. Henrik Zetterberg of the University of Gothenburg, as they explore the role of tau and neurodegeneration biomarkers in Alzheimer’s disease (AD).
Discover how the pathological ‘tau cascade’ can lead to neurodegeneration and learn about the evolving research landscape of tau and neurodegeneration biomarkers and how they can describe progression in AD.
Be part of the conversation during a live Q&A session moderated by Dr. Yuval Zabar of Biogen, giving you the opportunity to engage directly with leading experts in the field.
Date: 30 October 2025 
Time: 9:00 EDT, 14:00 CET
Reserve your spot now and stay informed on the evolving AD landscape.
This webinar has been organised and funded by Biogen.
This program is not eligible for CME credit.
Dr. Michelle Mielke and Prof. Henrik Zetterberg have been compensated by Biogen for their participation in this program.
This webinar is intended for healthcare professionals only.
Learning Objectives:
- Establish the physiological and pathological forms and functions of tau and explore the ‘tau cascade’ leading to neuronal dysfunction and neurodegeneration in AD
- Examine tau and neurodegeneration biomarkers and their relationships with AD pathology and clinical progression
- Navigate the current use of tau and neurodegeneration biomarkers and how they might evolve over time
Prof. Michelle Mielke, PhD (Speaker)
Professor of Epidemiology and Prevention, Public Health Sciences, and Professor of Gerontology and Geriatrics, Internal Medicine
Wake Forest University School of Medicine, Winston-Salem, North Carolina
Prof. Michelle Mielke is an acclaimed translational epidemiologist from Wake Forest University School of Medicine. Specializing in the etiology and epidemiology of neurodegenerative diseases, her research focuses on the utility of implementing blood-based biomarkers for screening and diagnosing Alzheimer’s disease (AD) and related dementias at the population level. She has been at the forefront of research understanding sex and gender differences in the development and progression of AD, has served as the Principal Investigator of several clinical- and epidemiological-based National Institutes of Health (NIH) grants and has published over 500 manuscripts. She is a Fellow in the American Association for the Advancement of Science (AAAS), Section on Neuroscience.
Prof. Henrik Zetterberg, MD, PhD (Speaker)
Professor of Neurochemistry and Clinical Chemist,
University of Gothenburg, Sweden, and University College London, UK
Prof. Henrik Zetterberg is a Professor of Neurochemistry in the UW Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, Madison, Wisconsin, the University of Gothenburg, Sweden, and University College London (UCL), UK. He is also a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK Dementia Research Institute (DRI) Fluid Biomarker Laboratory at UCL, and is a Key Member of the Hong Kong Center for Neurodegenerative Diseases. His main research focus and clinical interests are fluid biomarkers for brain diseases, particularly for neurodegenerative diseases. He has published over 2600 scientific articles and has received many awards.
Dr. Yuval Zabar, MD (Moderator)
Senior Medical Director, Global Medical – AD, Biogen
Yuval is a geriatric neurologist with over 20 years of experience as a clinical dementia specialist. Following fellowship training, he spent two decades at Lahey Hospital and Medical Center in Burlington, Massachusetts, where he built a clinical practice focused on the diagnosis and management of patients with Alzheimer’s disease (AD) and related dementias. In addition to patient care, he was an active clinical trialist, serving as an investigator on numerous interventional and biomarker-driven studies in AD and mild cognitive impairment. Over the past eight years at Biogen, he has led cross-functional medical initiatives, scientific engagement, and global education programs, with a focus on bridging clinical practice, research, and industry.
This webinar has been organised and funded by Biogen.
This program is not eligible for CME credit.
Dr. Michelle Mielke and Prof. Henrik Zetterberg have been compensated by Biogen for their participation in this program.
This webinar is intended for healthcare professionals only.
To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform created and funded by Biogen.
Veeva ID: Biogen-272260; Date of preparation: October 2025